Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Medical Faculty University Hospital Aachen, Rheinisch-Westfälische Technische Hochschule Aachen University, Aachen, Germany;
Department of Hematology and Oncology, Internal Medicine III, and.
Blood. 2015 Nov 26;126(22):2518-21. doi: 10.1182/blood-2015-03-633289. Epub 2015 Oct 20.
Acute intestinal graft-versus-host disease (aGVHD) refractory to immunosuppressive treatment is a serious complication after allogenic hematopoietic stem cell transplantation (HSCT). The underlying mechanisms of refractory aGVHD of the gut are not fully understood. Although telomere length (TL) reflects the replicative history of a cell, critically short telomeres have been associated with replicative exhaustion and tissue failure. In this study, we demonstrate that enterocytes of patients with refractory intestinal aGVHD show significantly increased proliferation, which translates into significant and critical telomere attrition following HSCT as compared with unaffected patients undergoing HSCT. Calculated telomere loss in aGVHD patients is 190 bp/wk, thereby massively exceeding physiological steady-state TL shortening rates such as in lymphocytes (∼50 bp/y). Our data support the hypothesis that increased compensatory proliferation following continued tissue damage can result in massive telomere loss in enterocytes of aGVHD patients. The present study introduces aGVHD-triggered increased cellular turnover and telomere loss with subsequent replicative exhaustion as a mechanism for refractory gut GVHD that is compatible with the long-term clinical aspect of the disease and provides a basis for stem cell protective therapies in the treatment of aGVHD.
急性肠道移植物抗宿主病(aGVHD)是异基因造血干细胞移植(HSCT)后的一种严重并发症,对免疫抑制治疗无反应。肠道难治性 aGVHD 的潜在机制尚未完全阐明。尽管端粒长度(TL)反映了细胞的复制历史,但关键的短端粒与复制衰竭和组织衰竭有关。在这项研究中,我们证明了难治性肠道 aGVHD 患者的肠细胞增殖显著增加,与接受 HSCT 的未受影响的患者相比,HSCT 后端粒损耗明显且严重。aGVHD 患者的端粒丢失计算为 190 bp/wk,大大超过了淋巴细胞等生理稳态 TL 缩短率(约 50 bp/y)。我们的数据支持这样一种假设,即持续的组织损伤后代偿性增殖会导致 aGVHD 患者肠细胞大量丢失端粒。本研究介绍了 aGVHD 引发的细胞更新和端粒丢失,随后发生复制衰竭,这是难治性肠道 GVHD 的一种机制,与疾病的长期临床方面相吻合,并为治疗 aGVHD 的干细胞保护治疗提供了基础。